Valuation: Curis, Inc.

Market Cap 3.35M 2.87M 2.68M 2.46M 4.62M 321M 4.71M 31.77M 12.38M 161M 12.59M 12.31M 532M P/E 2026 *
-0.07x
P/E 2027 * -0.22x
Enterprise Value 3.35M 2.87M 2.68M 2.46M 4.62M 321M 4.71M 31.77M 12.38M 161M 12.59M 12.31M 532M EV / Sales 2026 *
-
EV / Sales 2027 * 0.36x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Curis, Inc.

Manager TitleAgeSince
Chief Executive Officer 59 2018-09-23
Director of Finance/CFO 54 2022-08-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 2003-10-31
Chairman 84 2017-05-15
Director/Board Member 71 2010-06-02
Change 5-day change 1-year change 3-year change Capi.($)
+21.93%-18.62% - - 3.35M
+1.14%+3.46%+4.57%+24.14% 50.5B
-1.36%+4.82%+485.55%+614.84% 46.01B
-2.04%+3.69%+19.34%+91.23% 42.85B
+2.72%+6.02%+33.33%+19.66% 41.03B
0.00%-3.91%+17.87%+47.98% 32.02B
+0.72%+5.27%+31.55%+145.37% 16.98B
-1.85%+3.48% - - 17.05B
+3.06%+3.88%+5.81%+35.00% 14.3B
+0.50%+3.62%+82.64%+46.53% 13.84B
Average +2.48%+2.01%+85.08%+128.09% 30.51B
Weighted average by Cap. +0.18%+2.37%+105.24%+152.88%

Financials

2026 *2027 *
Net sales - 9.25M 7.92M 7.39M 6.78M 12.74M 885M 12.99M 87.66M 34.17M 444M 34.73M 33.98M 1.47B
Net income -52.02M -44.54M -41.55M -38.13M -71.65M -4.98B -73.06M -493M -192M -2.49B -195M -191M -8.26B -45.23M -38.73M -36.13M -33.16M -62.3M -4.33B -63.53M -429M -167M -2.17B -170M -166M -7.18B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-